Scandinavian Real Heart (SRH) 11 Implantation as Total Artificial Heart (TAH)-Experimental Update

Zoltán Szabó*, Jonas Holm, Azad Najar, Göran Hellers, Ina Laura Pieper, and Henrik Casimir Ahn

Department of Cardiothoracic Anesthesia, Linköping Heart and Medicine Center, University Hospital, S-581 85 Linköping, Sweden

*Corresponding author: Zoltán Szabó, Department of Cardiothoracic Anesthesia, Linköping Heart and Medicine Center, University Hospital, S-581 85 Linköping, Sweden
Tel: + 46 10 103 4178; Fax: + 46 13 10 02 46; E-mail: zoltan.szabo@regionostergotland.se

Received date: February 12, 2018; Accepted date: March 22, 2018; Published date: March 26, 2018

Copyright: © 2018 Szabó Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

One Swedish Landrace pig weighting approximately 80 kg was used to implant the SRH11. In this experiment the main focus was on the details of anesthesia as well as the mechanical function of the SRH11. The main finding from this study is that the SRH11 can deliver a wide range of cardiac output with a pulsatile waveform similar to the flow pattern of the native heart. In the anesthesia the following issues are of major importance from clinical point of view: the fluid balance and the adequate perfusions pressure is a high priority; The kidneys may be protected by a moderate dose of furosemide and measurement of urine output is mandatory; The systemic inflammatory reaction has to be controlled; At the weaning from the CPB the animal needs transfusion, therefore fresh blood should be available.

Keywords: Mechanical circulatory support; Total artificial heart; Assist device

Introduction

Heart failure (HF) is estimated to affect more than 35 million patients worldwide [1]. 5-25% of patients are expected to progress to severe HF despite optimal medical management [2]. A donor heart is the only cure, but the 5000 heart transplants performed annually worldwide do not meet the clinical need [3]. Mechanical circulatory support can be used as a bridge-to-transplant (BTT), to keep patients alive whilst on the waiting list, or as destination therapy (DT). The majority of patients are helped with a left ventricular assist device (LVAD), but the patients who have biventricular failure either require two continuous flow (CF) VADs or a total artificial heart (TAH), with a combined 1 year survival around 55% [4]. The only TAH currently on the market is the pneumatically-actuated Syncardia®, which has been implanted in >1,600 patients [5], and has successfully bridged about 80% of patients to transplant (with a 70% 1 year survival rate post-transplant) [6]. Limitations with pneumatics include noise, large diameter of the percutaneous drivelines [7], and restriction to mobility from carrying or wheeling around a pneumatic driver. Although the use of two CF-VADs offers a silent and mobile solution, the high morbidity and mortality means that there is still a clinical need for a superior solution for patients requiring biventricular support [8]. The electrically-hydraulically-actuated Carmat® TAH which is currently in clinical trials [9] addressed many of pneumatically-related issues, but the large size is a disadvantage. By removing hydraulics from its design, ReinHeart has achieved a compact size which is being evaluated in chronic animal studies [10]. Similarly, Scandinavian RealHeart (SRH) has also opted for an electrically-actuated TAH design, and thus addresses all issues related to pneumatics. The first aim of our study was to test the hemodynamics generated by the prototype version SRH11 when both the stroke volume and stroke rate were manipulated. Our second aim was to observe the character of the arterial pulse curve during the testing and observe the clinically important moments during anesthesia.

Materials and Methods

Total artificial heart Real Heart prototype SRH11

The uniqueness in RealHeart's approach is that it mimics the design and the main pumping principle of the natural human heart. RealHeart is invented by Dr Azad Najar and consists of four chambers, two atria and two ventricles, separated by an atrioventricular (AV) plane with valves. AV-plane movement accounts for 60% of the left ventricular stroke volume in humans [11], and is the pumping principle employed in RealHeart. The TAH consists of two independently operated left and right pumps, which enables adjustment to the left flow=volume to compensate for the bronchial circulation. The two pumps create a synchronous pulsatile outflow, and continuous passive inflow. The atria are filled passively and are compliant to minimize upstream suction events, (Figures 1 and 2). The atria fill with blood both during systole and diastole, so there is no stop in blood flow during ventricle ejection as seen with other piston-pump designs. This should, in theory, reduce upstream pressure build-up, and thereby the risk for respiratory failure. The SRH11 prototype weighed 800 g and its inflow and outflow connections were optimized for the pig anatomy.
Animal model

One 80 kg specially-bred Swedish land race pig (Sus Scrofa) was used for this research. The experiment was approved by the local ethical board [12].

Surgical procedure

After stress relief, the animal was premedicated with Zoletil® (Zoletil- Virdac France, containing tiletamine 25 mg/ml, zolazepam 25 mg/ml, and Dextrodomitor, Orion Pharma, 0.5 mg dexmedetomidinhydrochloride, corresponding to 0.42 mg/ml dexmedetomidine). More details of the anesthetic technique are provided in our previous publication [12]. The pain relief was tested by pinching the pig’s hind limbs. Intubation was carried out and the animal was ventilated throughout the experiment with FiO2 21% using a Siemens Servo ventilator 900 D (Siemens, Siemens Healthcare, Stockholm, Sweden). The right carotid artery and the right internal jugular vein were also cannulated in the same wound on the neck. The arterial pressure was measured by strain gauge and the core temperature was recorded 30 cm from the nose in the esophagus. We monitored ECG lead II. Before starting the cardiopulmonary bypass (CPB) the animal was anticoagulated with heparin mg/kg BW. The anticoagulant effect was measured with ACT and a minimum 480 s was considered acceptable to start the CPB. After connecting the animal to CPB, bypass was instituted and the operation was then carried out on the empty beating heart. The right ventricle was incised 1 cm from the right atrium at the level of the right atrial appendix. The incision was extended along this border towards cava inferior and further 1 cm above the coronary sinus to the ventricular septum which was cut into the left ventricle. The incision was then carried out in the left ventricle (LV) 1 cm from the left atrium and to the left atrial appendix. The roof of the left atrium (LA) was cut towards the superior vena cava. Then the pulmonary trunk and aorta were transected distally and the heart removed. In this way we saved all tissue of the right atrium (RA) and LA for the connection with the TAH. Anastomoses were made with continuous suture between the atria and the pump cuffs and between the pump grafts and the pulmonary artery and aorta. The implantation of the SRH11 was done similar to earlier experience described detailed in our earlier publication [12].

Results

The preparation for CPB took 33 min. A bolus of 2 mg i.v. metoprolol was needed before cannulation of the heart to prevent atrial fibrillation and ventricular arrhythmias. The duration of the CPB was almost 4 h. The ACT before the CPB was 750 sec and throughout the CPB it varied between 582 – and >999 sec. The temperature was kept at +36.7–36.8°C. At the end of the experiment the temperature dropped to +34.5°C despite warming with a thermal ceiling. The hematocrit as measured by the heart lung machine was 18-24%. No hemolysis in the urine was noted. During the CPB Noradrenalin 40 microgram/ml was needed at a rate of 1-3 ml/h. The fluid balance was +11,150 ml. Urine output: 1,950 ml. 10 mg intravenous furosemid was required to increase the urine output and decrease the renal tubular oxygen demand. Transfusion of 2,500 ml fresh blood from another pig was used to fill the animal during weaning from the CPB. Throughout the CPB support, an arterial pressure of 60-80 mmHg was maintained. The peripheral vasoconstriction made the arterial saturation’s measurement impossible. The filling pressure was measured in some points with wireless micro pressure sensors (ISS Inc., Ypsilanti, MI, US) which were checked with an antenna [13]. The measurement was of good quality and such devices can be safely used at the same time when SRH11 is implanted. At the weaning the experimental animal's hematocrit was 23%. The data of how the SRH11 was tested are shown in the (Table 1). The SRH11 was run for 65 min without problems. The mean systolic blood pressure in the aorta was 77 mmHg, and the diastolic blood pressure was slightly above 20 mmHg, likely due to hemodilution and relatively low pump output.

| Stroke volume ml | Frequency beat/minute | Cardiac output ml/min | Measurement of filling P in the pulm. artery/SAP |
|------------------|-----------------------|-----------------------|-----------------------------------------------|
| SRH11            | SRH11                 | SRH11                 |                                               |
| 5                | 15                    | 75                    |                                               |
| 10               | 20                    | 200                   |                                               |
waveform similar to the flow pattern of the native heart. With more detailed analysis you can also observe a dicrotic notch in the arterial recording.

**Table 1:** Data under weaning measured on the SRH11 and some pressure values. *Are data obtained with IYSS pressure sensors.

| Pump output |          |
|-------------|----------|
| 20          | 30       | 600      |
| 25          | 30       | 750      |
| 20          | 25       | 500      |
| 20          | 35       | 700      |
| 20          | 50       | 1000     |
| 25          | 60       | 1500     |
| 30          | 60       | 1800     |
| 30          | 65       | 1950     |
| 35          | 65       | 2275     |
| 30          | 60       | 1800     |
| 30          | 65       | 1950     |
| 30          | 70       | 2100     |
| 30          | 75       | 2250     |
| 30          | 80       | 2400     |
| 30          | 85       | 2550     |
| 30          | 90       | 2700     |
| 30          | 95       | 2850     |
| 30          | 90       | 2700     |
| 25          | 90       | 2250     |
| 25          | 95       | 2375     |
| 30          | 85       | 2250     |
| 30          | 90       | 2700     |
| 30          | 90       | 2700     |
| 30          | 100      | 3000     |
| 30          | 105      | 3150     |
| 32          | 105      | 3360     |
| 30          | 100      | 3000     |
| 30          | 105      | 3150     |
| 30          | 100      | 3000     |
| 30          | 110      | 3300     |
| 30          | 120      | 3600     |
| 40          | 120      | 4800     |
| 40          | 125      | 5000     |

**Discussion**

The main finding from this study is that the SRH11 can deliver a wide range of cardiac output with a pulsatile waveform similar to the flow pattern of the native heart. However, the fluid overload may put an excessive burden on the lungs, as we measured 30 mmHg in the pulmonary artery, and 0 mmHg in the vena pulmonalis immediately before the left atrium. The balance of +11 liter was too much and needs to be better controlled in the future. More specifically, the systemic inflammatory reaction needs to be suppressed with corticosteroids, and the decrease in oncotic pressure with an infusion of albumin. The pump output has to be raised more promptly than we did here to reach the optimal cardiac output corresponding to the animal’s weight and temperature. The systolic arterial pressure needs to be increased to around 70-80 mmHg, which is typically achieved in cardiac surgery patients after CPB.

**Conclusion**

The SRH11 can deliver a wide range of cardiac output with a pulsatile waveform similar to the flow pattern of the native heart. The equilibrium between the fluid balance and the adequate perfusion pressures are a high priority. The kidneys may be protected by a moderate dose of furosemid and measurement of urine output is mandatory. Fresh blood has to be available at the weaning from CPB to fill the animal and the SRH11. The generated pressure curve is physiologic and displays a dicrotic notch. The systemic inflammatory reaction has to be controlled.

**Acknowledgement**

The authors are grateful to Dan Linghammar for supervising the experimental process from the veterinary point of view and generous assistance at the experimental laboratory. To Magnus Rosen, Anders Svensson perfusionists, and Ana Nilsson, Emma Berglund and Malin Arodell theater nurses. The authors are also grateful to Hejdlösa Bilder.
AB’s photographer Lasse Hejdenberg from Linköping for excellent photo and film documentation of the whole process. We are grateful to ISS Inc. (Ypsilanti, MI, US) for assisting us with pressure sensor and measurements during presented experiment.

Conflicts of Interest

Henrik Ahn and Zoltán Szabó received compensation from Scandinavian Real Heart for the experimental research work, but not for preparing the manuscript. Authors Azad Najar, Göran Hellers, and Ina Laura Pieper hold positions and own stock in Scandinavian Real Heart. Jonas Holm has no conflicts of interest.

References

1. Ziaeian B, Fonarow GC (2016) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13: 368-378.
2. Chaudhry SP, Stewart GC (2016) Advanced heart failure: Prevalence, natural history, and prognosis. Heart Fail Clin 12: 323-333.
3. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, et al. (2009) Advanced heart failure treated with continuous-flow left ventricular assist device. J Heart Lung Transplant 28: 2241-2251.
4. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. (2017) Eighth annual intermacs report: Special focus on framing the impact of adverse events. J Heart Lung Transplant 36: 1080-1086.
5. Strickland E (2017) A make-or-break year for artificial hearts. IEEE Spectrum 54: 30-31.
6. Copeland JG (2013) Syncardia total artificial heart: Update and future. Tex Heart Inst J 40: 587-588.
7. Pagani FD, Miller LW, Russell SD Aaronson KD, John R, et al. (2009) Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 54: 312-321.
8. Arabia FA, Milano CA, Mahr C Mc, Gee EC, Mokadam NA, et al. (2017) Biventricular support with intracorporeal, continuous flow, centrifugal ventricular assist devices. Ann Thorac Surg 105: 548-555.
9. Latrémouille C, Carpentier A, Leprince P, Roussel JC, Cholley B, et al. (2017) A bioprosthetic total artificial heart for end-stage heart failure: Results from the pilot study. J Heart Lung Transplant 37: 33-37.
10. Laumen M, Finocchiaro T, Cuenca E, Guersoy D, Spiliopoulos S, et al. (2013) A novel total artificial heart for destination therapy: In-vitro and in-vivo study. Biomed Tech.
11. Carlsson M, Ugander M, Mosén H, Buhre T, Arheden H (2007) Atrioventricular plane displacement is the major contributor to left ventricular pumping in healthy adults, athletes, and patients with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 292: 452-459.
12. Szabó Z, Holm J, Najar A, Hellers G, Ahn H (2017) Early experience of implantation of a new pulsatile total artificial heart (tah) in the pig. J Clin Exp Cardiolog 8: 510.
13. Hubbert L, Baranowski J, Delshad B, Ahn H (2017) Left atrial pressure monitoring with an implantable wireless pressure sensor after implantation of a left ventricular assist device. ASAIO J 63: e60-e65.